Monday, July 17, 2023

Readout AI Gets Funding For Clinical Trial Software

Los Angeles-based Readout AI has raised a pre-seed funding round, which will help it "turbocharge the biostatistical and medical writing tasks associated with clinical trials." Size of the funding was not announced. According to the company, the funding was led by Meridian Street Capital, with participation from Mucker Capital, Necessary Ventures, and angel investor Ryan Fukushima (COO of Tempus and CEO of Pathos). The CEO of Readout AI is Matthew Michelson and its co-founder is Michael Shleifer. The company said its platform "automatically analyzes data with the appropriate statistics and then describes the results in formats ranging from table descriptions to abstracts to posters."